Skip to content

Precigen PGEN Cash, Cash Equivalents, and Marketable Securities

Cash, Cash Equivalents, and Marketable Securities at other companies

Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$585.84M-6.7%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$461.4M-21.4%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$694.16M+280%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Amgen logo
AmgenAMGN

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$1.91B+213%
Enterprise value$2B+234%
P/S72×

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Debt / equity4.9×
Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's cash, cash equivalents, and marketable securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Precigen's cash, cash equivalents, and marketable securities?
Precigen (PGEN) reported cash, cash equivalents, and marketable securities of $49.26M in Q1 2026.
How has Precigen's cash, cash equivalents, and marketable securities changed year-over-year?
Precigen's cash, cash equivalents, and marketable securities decreased by 34.3% year-over-year, from $74.93M to $49.26M.
What is the long-term trend for Precigen's cash, cash equivalents, and marketable securities?
Over 5 years (2020 to 2025), Precigen's cash, cash equivalents, and marketable securities has grown at a 7.7% compound annual growth rate (CAGR), from $48.33M to $70.14M.
What does cash, cash equivalents, and marketable securities mean?
This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term investments that can be readily converted into cash. It serves as the primary buffer for operational liquidity and potential capital allocation activities. Investors monitor this to assess the company's ability to meet short-term obligations and fund growth initiatives.